This is accomplished by using a ‘2 × 2’ dosing scheme, where the second cycle of [177Lu]Lu-PSMA-I&T is administered almost directly after wash-out of the tumor exposure from the previous cycle. The gene discussed is FOLH1; the disease is neoplasm.